More on ABBV
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $255.00 |
|
|||
| Open | $253.92 | ||||
| 52 Wk High | $68.12 | ||||
| 52 Wk Low | $50.71 | ||||
| Day High | $259.61 | ||||
| Day Low | $253.92 | ||||
| P/E | 55.77 | ||||
| EPS | $4.61 | ||||
| Volume | 4,308,855 | ||||
- AbbVie (ABBV) Declares $1.73 Quarterly Dividend; 2.7% Yield
- AbbVie Declares Quarterly Dividend
- AbbVie atogepant meets all endpoints in menstrual migraine Phase 3 trial
- AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
- Abbvie (ABBV) PT Raised to $315 at HSBC
- Abbvie (ABBV) PT Raised to $282 at BofA Securities
- AbbVie's etentamig meets Phase 3 endpoints in multiple myeloma trial
- AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multi
- Form 8-K AbbVie Inc. For: Sep 03
- AbbVie completes $10.9B acquisition of Apogee Therapeutics
Entities mentioned with ABBV
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Dividend | View Related Stories »
- Show More...
